Sangamo Therapeutics Inc

Insider selling at Sangamo Therapeutics signals caution for investors, as executive sales surge amid stalled gene‑therapy progress and falling analyst ratings.

Insightful insider RSU activity at Sangamo Therapeutics shows senior execs are committed to the gene‑editing pipeline, not quick sales—good news for long‑term investors.